Goldman Sachs
LABP

Goldman Sachs’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Goldman Sachs’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,309
Closed -$9K – 6401
2022
Q3 		$9K Sell
1,309
-2,971
-69% -$25.8K ﹤0.01% 6039
2022
Q2 		$31K Buy
4,280
+2,326
+119% +$21.2K ﹤0.01% 6122
2022
Q1 		$29K Buy
1,954
+197
+11% +$5.01K ﹤0.01% 6363
2021
Q4 		$84K Buy
+1,757
New +$185K ﹤0.01% 6172

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's LABP Position: Q4 2022 in Review

Goldman Sachs sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q4 2022, closing a stake of 1,309 shares — an estimated $9K sold.

Goldman Sachs first reported a position in LABP in Q4 2021 and held it in 4 quarters. The position peaked at $84K in Q4 2021. 23 funds tracked by Wall St. Rank hold LABP as of Q4 2022.

  • Goldman Sachs reported no remaining Landos Biopharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 1,309 Landos Biopharma, Inc. Common Stock shares in Q4 2022, an estimated $9K.
  • Goldman Sachs first reported a position in Landos Biopharma, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • Goldman Sachs's Landos Biopharma, Inc. Common Stock position peaked at $84K in Q4 2021.
  • 23 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.